Black Rock Inc. Red Hill Biopharma Ltd. Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.5 - $523.8 $8,691 - $9.11 Million	-17,383 Reduced 4.87%	339,292 $171,000
Q2 2022 Aug 12, 2022	SELL	$0.63 - $2.58 $515 - $2,110	-818 Reduced 0.23%	356,675 $311,000
Q1 2022 May 12, 2022	BUY	$1.65 - $3.12 $92,693 - $175,275	56,178 Added 18.64%	357,493 $901,000
Q4 2021 Feb 10, 2022	SELL	$2.31 - $5.85 $25,003 - $63,320	-10,824 Reduced 3.47%	301,315 $778,000
Q3 2021 Nov 09, 2021	BUY	$4.55 - $10.36 $108,180 - $246,319	23,776 Added 8.25%	312,139 $1.43 Million
Q2 2021 Aug 11, 2021	BUY	$5.98 - $7.51 $1.72 Million - $2.17 Million	288,363 New	288,363 $1.98 Million

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $364M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.